Congenital Bleeding Disorder Clinical Trials

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

NCT01862367

Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency
Locations: Novo Nordisk Investigational Site Orange, California, United States

Novo Nordisk Investigational Site Tampa, Florida, United States

Novo Nordisk Investigational Site Atlanta, Georgia, United States

Novo Nordisk Investigational Site Detroit, Michigan, United States

View all 17 locations

View Trial Details

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

NCT01228669

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +12 more
Locations: Novo Nordisk Investigational Site Vienna, Austria

Novo Nordisk Investigational Site Copenhagen, Denmark

Novo Nordisk Investigational Site Berlin, Germany

Novo Nordisk Investigational Site Frankfurt/M., Germany

View all 16 locations

View Trial Details

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A

NCT02941354

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Chicago, Illinois, United States

Novo Nordisk Investigational Site Peoria, Illinois, United States

Novo Nordisk Investigational Site Memphis, Tennessee, United States

Novo Nordisk Investigational Site Richmond, Virginia, United States

View all 15 locations

View Trial Details

Completed

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

NCT02541942

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Locations: Novo Nordisk Investigational Site Tucson, Arizona, United States

Novo Nordisk Investigational Site Tampa, Florida, United States

Novo Nordisk Investigational Site Atlanta, Georgia, United States

Novo Nordisk Investigational Site Iowa City, Iowa, United States

View all 15 locations

View Trial Details

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

NCT00951405

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Locations: Novo Nordisk Investigational Site Little Rock, Arkansas, United States

Novo Nordisk Investigational Site Los Angeles, California, United States

Novo Nordisk Investigational Site Orange, California, United States

Novo Nordisk Investigational Site Tampa, Florida, United States

View all 25 locations

View Trial Details

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

NCT01395810

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +9 more
Locations: Novo Nordisk Investigational Site Los Angeles, California, United States

Novo Nordisk Investigational Site San Francisco, California, United States

Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States

Novo Nordisk Investigational Site Jacksonville, Florida, United States

View all 49 locations

View Trial Details

Completed

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

NCT00978380

Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency
Locations: Novo Nordisk Investigational Site Orange, California, United States

Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States

Novo Nordisk Investigational Site Tampa, Florida, United States

Novo Nordisk Investigational Site Atlanta, Georgia, United States

View all 34 locations

View Trial Details

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A

NCT02920398

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations: Novo Nordisk Investigational Site Torrance, California, United States

Novo Nordisk Investigational Site Iowa City, Iowa, United States

Novo Nordisk Investigational Site Baltimore, Maryland, United States

Novo Nordisk Investigational Site Dayton, Ohio, United States

View all 14 locations

View Trial Details

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B

NCT01386528

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +9 more
Locations: Novo Nordisk Investigational Site Los Angeles, California, United States

Novo Nordisk Investigational Site San Francisco, California, United States

Novo Nordisk Investigational Site Washington D.C., District of Columbia, United States

Novo Nordisk Investigational Site Augusta, Georgia, United States

View all 41 locations

View Trial Details

Completed

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

NCT01333111

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +9 more
Locations: Novo Nordisk Investigational Site Los Angeles, California, United States

Novo Nordisk Investigational Site Jacksonville, Florida, United States

Novo Nordisk Investigational Site Augusta, Georgia, United States

Novo Nordisk Investigational Site Iowa City, Iowa, United States

View all 43 locations

View Trial Details

Congenital Bleeding Disorder

Congenital Bleeding Disorder trial results

Related conditions